BRAF Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
BRAF Tests Market Report Overview
The BRAF Tests market size was valued at $32.8 million in 2023. The market is expected to grow at a CAGR of more than 6% during 2023-2033. BRAF Sanger sequencing Tests are used when complete sequencing of the BRAF gene is required for accurate detection and mapping of mutations. Sanger sequencing is a DNA sequencing technique that uses modified, chain-terminating dideoxynucleotides (ddNTPs).
BRAF Tests Market Outlook 2023-2023 ($ Million)
Buy The Full Report for More Insights on The BRAF Tests Market Forecast
The BRAF Tests market research report explains the market behavior, which will help identify quantitative market trends within the In Vitro Diagnostics therapeutic area. The model discusses in detail the impact of COVID-19 on the BRAF Test market for the year 2020 and beyond. The report has extensively covered pipeline products and technologies, which will help in identifying companies with the most robust pipeline. This, in turn, will assist in predictive analysis for designing in-licensing and out-licensing strategies.
Market Size (2023) | $32.8 Million |
CAGR (2023-2033) | >6% |
Historic Period | 2015-2022 |
Forecast Period | 2023-2033 |
Key Segments | · BRAF Tests
· Next Generation Sequencing (NGS) Tests |
Key Regions | · Asia-Pacific
· Europe · Middle East and Africa · North America · South and Central America |
Key Companies | · Roche Diagnostics International Ltd
· bioMerieux SA · Qiagen NV · Agilent Technologies Inc · Illumina Inc |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
BRAF Tests Market Dynamics
The BRAF Test market is expected to grow across all regions during the forecast period. This growth is attributed to increasing incidence of melanoma, colorectal, and lung cancers and rising awareness of the condition. Furthermore, improved accessibility to personalized medicine in emerging economies and technological advancements such as next-generation sequencing (NGS) will propel the growth of the market in focus. However, GlobalData predicts the use of less sensitive methods, such as Sanger Sequencing, to decrease during the forecast period, while NAAT will remain prevalent in most countries.
BRAF Tests Market Segments
The key segments in the BRAF Tests market are BRAF Tests and Next Generation Sequencing (NGS) Tests. Next Generation Sequencing (NGS) Tests led the BRAF Tests market in 2023. NGS refers to high-throughput methods for DNA sequencing that are not Sanger-based. NGS technology has largely superseded Sanger sequencing in academic or genome research and is increasingly being applied in clinical practice.
BRAF Tests Market Analysis by Segments, 2023 (%)
Buy The Full Report to Know More About the BRAF Tests Market Segments
BRAF Tests Market Segmentation by Regions
The key regions in the BRAF Tests market are Asia-Pacific, Europe, the Middle East and Africa, North America, and South and Central America. In 2023, Europe dominated the BRAF Tests market owing to government initiatives of many European countries. For instance, Recently European Society for Medical Oncology (ESMO) recommended BRAF testing for all metastatic melanoma, mCRC, and lung cancer patients at the time of diagnosis. ESMO is a group of 26 European countries.
BRAF Tests Market Analysis by Regions, 2023 (%)
Buy The Full Report for More Regional Insights into The BRAF Tests Market
BRAF Tests Market – Competitive Landscape
The key companies in the BRAF Tests market are:
- Roche Diagnostics International Ltd
- bioMerieux SA
- Qiagen NV
- Agilent Technologies Inc
- Illumina Inc
In 2023, Roche Diagnostics International Ltd accounted for the highest BRAF Tests market share, followed by bioMerieux SA.
BRAF Tests Market Analysis by Companies, 2023 (%)
Buy The Full Report for More Company Insights into The BRAF Tests Market
Segments Covered in this Report
BRAF Tests Segment Outlook ($ Million, 2015-2033)
- BRAF Tests
- Next Generation Sequencing (NGS) Tests
BRAF Tests Regional Outlook ($ Million, 2015-2033)
- Asia-Pacific
- Europe
- Middle East and Africa
- North America
- South and Central America
Key Inclusions of the market model are -
Currently marketed BRAF Tests market and evolving competitive landscape:
- Insightful review of the key industry trends.
- Annualized total BRAF Tests market revenue by segment and market outlooks from 2015-2033.
- Market-level data on units, average selling prices, and market values.
Global, Regional, and Country level market specific insights:
- Qualitative market-specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country-specific insights on the market.
- SWOT analysis for the BRAF Tests market.
- Competitive dynamics insights and trends provided for the BRAF Tests market.
Get in-depth understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
- Country-specific overview of the healthcare system.
- Country-specific reimbursement policies.
- Country-specific medtech regulatory landscape.
Our robust methodologies and sources enable the model to provide an extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real-world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: F. Hoffmann-La Roche Ltd, bioMerieux SA, Qiagen NV, Agilent Technologies Inc, Illumina Inc, Thermo Fisher Scientific Inc, Abbott Laboratories, Takara Bio Inc, New England Biolabs Inc, Amoy Diagnostics Co Ltd, Biocartis Group NV, BGI Genomics Co Ltd, and others.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.
Scope
This report provides:
- Insightful review of the key industry trends.
- Annualized total BRAF Tests market revenue by segment and market outlooks.
- Market-level data on units, average selling prices, and market values.
- Global, regional, and country-level market-specific insights including qualitative market-specific information with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country-specific insights on the market.
- SWOT analysis for the BRAF Tests market.
- Competitive dynamics insights and trends provided for the BRAF Tests market.
- Country-specific overview of the healthcare system.
- Country-specific reimbursement policies.
- Country-specific medtech regulatory landscape.
Reasons to Buy
- Understand the impact of COVID-19 on BRAF Tests.
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving BRAF Tests.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the BRAF Test market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company’s share of market leaders.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track device sales in the global and country-specific BRAF Tests market from 2015-2033.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
bioMerieux SA
Qiagen NV
Agilent Technologies Inc
Illumina Inc
Thermo Fisher Scientific Inc
Abbott Laboratories
Takara Bio Inc
New England Biolabs Inc
Amoy Diagnostics Co Ltd
Biocartis Group NV
BGI Genomics Co Ltd
Frequently asked questions
-
What was the BRAF Tests market size in 2023?
The BRAF Tests market size was $32.8 million in 2023.
-
What will the growth rate of the BRAF Test market be during the forecast period?
The BRAF Tests market is expected to grow at a CAGR of more than 6% during 2023-2033.
-
Which was the leading segment in the BRAF Test market?
The Next Generation Sequencing (NGS) Tests segment was leading the BRAF Tests market.
-
Which region dominated the BRAF Tests market in 2023?
Europe was the largest regional segment of the BRAF Tests market in 2023.
-
Which are the key companies operating in the BRAF Test market?
The key companies in the BRAF Test market are Roche Diagnostics International Ltd, bioMerieux SA, Qiagen NV, Agilent Technologies Inc., and Illumina Inc. among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.